Comprehensive Analysis of Hypermutation in Human Cancer

Cell

Volumn 171, Issue 5, 2017, Pages 1042-1056.e10

  Campbell, Brittany B ^a,b   Light, Nicholas ^a,b   Fabrizio, David ^c   Zatzman, Matthew ^a,b   Fuligni, Fabio ^a   de Borja, Richard ^a   Davidson, Scott ^a   Edwards, Melissa ^a   Elvin, Julia A ^c   Hodel, Karl P ^c   Zahurancik, Walter J ^d   Suo, Zucai ^d   Lipman, Tatiana ^a   Wimmer, Katharina ^e   Kratz, Christian P ^f   Bowers, Daniel C ^g,h   Laetsch, Theodore W ^g,h   Dunn, Gavin P ⁱ   Johanns, Tanner M ⁱ   Grimmer, Matthew R ⁱ   Smirnov, Ivan V ^j   Larouche, Valérie ^k   Samuel, David ^l   Bronsema, Annika ^m   Osborn, Michael ⁿ   Stearns, Duncan ^o   Raman, Pichai ^p,q   Cole, Kristina A ^p,q   Storm, Phillip B ^p   Yalon, Michal ^r   Opocher, Enrico ^s   Mason, Gary ^t   Thomas, Gregory A ^u   Sabel, Magnus ^v   George, Ben ^w   Ziegler, David S ^x,y   Lindhorst, Scott ^z   Issai, Vanan Magimairajan ^aa   Constantini, Shlomi ^ab   Toledano, Helen ^ab   Elhasid, Ronit ^ad   Farah, Roula ^ae   Dvir, Rina ^ab,ac   Dirks, Peter ^a   Huang, Annie ^a,b   Galati, Melissa A ^a   Chung, Jiil ^a   Ramaswamy, Vijay ^a   Irwin, Meredith S ^a   Aronson, Melyssa ^af   Durno, Carol ^a,af   Taylor, Michael D ^a   Rechavi, Gideon ^r   Maris, John M ^p,q   Bouffet, Eric ^a   Hawkins, Cynthia ^a   Costello, Joseph F ^j   Meyn, M Stephen ^b,ag   Pursell, Zachary F ^c   Malkin, David ^a,ah   Tabori, Uri ^a   Shlien, Adam ^a,b   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Center for Cancer and Blood Disorders   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k University Laval   (Canada)

^l Valley Children's Hospital   (United States)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁿ WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^o CASE WESTERN RESERVE UNIVERSITY   (United States)

^p CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^q UNIVERSITY OF PENNSYLVANIA   (United States)

^r SHEBA MEDICAL CENTER   (Israel)

^s UNIVERSITY OF PADOVA   (Italy)

^t CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^u OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^v QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^w MEDICAL COLLEGE OF WISCONSIN   (United States)

^x SYDNEY CHILDREN'S HOSPITAL   (Australia)

^y UNIVERSITY OF NEW SOUTH WALES   (Australia)

^z MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^aa UNIVERSITY OF MANITOBA   (Canada)

^ab TEL AVIV UNIVERSITY   (Israel)

^ac SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^ad TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^ae Saint George Hospital University Medical Center   (Israel)

^af MOUNT SINAI HOSPITAL   (Canada)

^ag UNIVERSITY OF WISCONSIN MADISON   (United States)

^ah UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

cancer genomics; cancer predisposition; DNA repair; DNA replication; hypermutation; immune checkpoint inhibitors; mismatch repair; mutator

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; FEMALE; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; HYPERMUTATION; LIMIT OF QUANTITATION; MALE; MALIGNANT NEOPLASM; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRAVIOLET RADIATION; CHILD; CLASSIFICATION; CLUSTER ANALYSIS; GENETICS; MUTATION; NEOPLASM; PATHOLOGY;

DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED DNA POLYMERASE GAMMA; POLD1 PROTEIN, HUMAN; POLE PROTEIN, HUMAN; POLY ADP RIBOSE BINDING PROTEIN;

ADULT; CHILD; CLUSTER ANALYSIS; DNA POLYMERASE II; DNA POLYMERASE III; DNA REPLICATION; HUMANS; MUTATION; NEOPLASMS; POLY-ADP-RIBOSE BINDING PROTEINS;

EID: 85031810803     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.09.048     Document Type: Article

References (48)

1. Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., Amin, S.B., Arachchi, H., Arora, A., Auman, J.T., Ayala, B., et al., Cancer Genome Atlas Network. Genomic classification classification of cutaneous melanoma. Cell 161 (2015), 1681–1696.
2. Albertson, T.M., Ogawa, M., Bugni, J.M., Hays, L.E., Chen, Y., Wang, Y., Treuting, P.M., Heddle, J.A., Goldsby, R.E., Preston, B.D., DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc. Natl. Acad. Sci. USA 106 (2009), 17101–17104.
3. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium, ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
4. Amayiri, N., Tabori, U., Campbell, B., Bakry, D., Aronson, M., Durno, C., Rakopoulos, P., Malkin, D., Qaddoumi, I., Musharbash, A., et al., BMMRD Consortium. High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int. J. Cancer 138 (2016), 380–385.
5. Bouffet, E., Larouche, V., Campbell, B.B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34 (2016), 2206–2211.
6. Campbell, J.D., Alexandrov, A., Kim, J., Wala, J., Berger, A.H., Pedamallu, C.S., Shukla, S.A., Guo, G., Brooks, A.N., Murray, B.A., et al., Cancer Genome Atlas Research Network. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48 (2016), 607–616.
7. Chalmers, Z.R., Connelly, C.F., Fabrizio, D., Gay, L., Ali, S.M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med., 9, 2017, 34.
8. Daee, D.L., Mertz, T.M., Shcherbakova, P.V., A cancer-associated DNA polymerase delta variant modeled in yeast causes a catastrophic increase in genomic instability. Proc. Natl. Acad. Sci. USA 107 (2010), 157–162.
9. Diaz, L.A. Jr., Le, D.T., PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med., 373, 2015, 1979.
10. Dossett, L.A., Harrington, M., Cruse, C.W., Gonzalez, R.J., Cutaneous angiosarcoma. Curr. Probl. Cancer 39 (2015), 258–263.
11. Durno, C.A., Sherman, P.M., Aronson, M., Malkin, D., Hawkins, C., Bakry, D., Bouffet, E., Gallinger, S., Pollett, A., Campbell, B., Tabori, U., International BMMRD Consortium. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. Eur. J. Cancer 51 (2015), 977–983.
12. Esteban-Jurado, C., Giménez-Zaragoza, D., Muñoz, J., Franch-Expósito, S., Álvarez-Barona, M., Ocaña, T., Cuatrecasas, M., Carballal, S., López-Cerón, M., Marti-Solano, M., et al. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget 8 (2017), 26732–26743.
13. Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., Schnall-Levin, M., White, J., Sanford, E.M., An, P., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31 (2013), 1023–1031.
14. Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N.D., Kanchi, K.L., Maher, C.A., Fulton, R., Fulton, L., Wallis, J., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150 (2012), 1121–1134.
15. Herr, A.J., Ogawa, M., Lawrence, N.A., Williams, L.N., Eggington, J.M., Singh, M., Smith, R.A., Preston, B.D., Mutator suppression and escape from replication error-induced extinction in yeast. PLoS Genet., 7, 2011, e1002282.
16. Johanns, T.M., Miller, C.A., Dorward, I.G., Tsien, C., Chang, E., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R.E., Dahiya, S., et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6 (2016), 1230–1236.
17. Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., et al., Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497 (2013), 67–73.
18. Kane, D.P., Shcherbakova, P.V., A common cancer-associated DNA polymerase ε mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res. 74 (2014), 1895–1901.
19. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
20. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al., Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536 (2016), 285–291.
21. Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv, arXiv:1303.3997, https://arxiv.org/abs/1303.3997.
22. Miller, C.A., White, B.S., Dees, N.D., Griffith, M., Welch, J.S., Griffith, O.L., Vij, R., Tomasson, M.H., Graubert, T.A., Walter, M.J., et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol., 10, 2014, e1003665.
23. Morganella, S., Alexandrov, L.B., Glodzik, D., Zou, X., Davies, H., Staaf, J., Sieuwerts, A.M., Brinkman, A.B., Martin, S., Ramakrishna, M., et al. The topography of mutational processes in breast cancer genomes. Nat. Commun., 7, 2016, 11383.
24. Muggeo, V.M.R., Estimating regression models with unknown break-points. Stat. Med. 22 (2003), 3055–3071.
25. Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., et al., Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
26. Nguyen, S.A., Stechishin, O.D., Luchman, H.A., Lun, X.Q., Senger, D.L., Robbins, S.M., Cairncross, J.G., Weiss, S., Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin. Cancer Res. 20 (2014), 4894–4903.
27. Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L.B., Martin, S., Wedge, D.C., et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534 (2016), 47–54.
28. Pfeifer, G.P., You, Y.H., Besaratinia, A., Mutations induced by ultraviolet light. Mutat. Res. 571 (2005), 19–31.
29. Pleasance, E.D., Stephens, P.J., O'Meara, S., McBride, D.J., Meynert, A., Jones, D., Lin, M.L., Beare, D., Lau, K.W., Greenman, C., et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463 (2010), 184–190.
30. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
31. Roberts, S.A., Lawrence, M.S., Klimczak, L.J., Grimm, S.A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G.V., Carter, S.L., Saksena, G., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45 (2013), 970–976.
32. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B.S., Swanton, C., DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol., 17, 2016, 31.
33. Sage, E., Distribution and repair of photolesions in DNA: genetic consequences and the role of sequence context. Photochem. Photobiol. 57 (1993), 163–174.
34. Santin, A.D., Bellone, S., Buza, N., Choi, J., Schwartz, P.E., Schlessinger, J., Lifton, R.P., Regression of chemotherapy-resistant polymerase ε (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin. Cancer Res. 22 (2016), 5682–5687.
35. Scarpa, A., Chang, D.K., Nones, K., Corbo, V., Patch, A.M., Bailey, P., Lawlor, R.T., Johns, A.L., Miller, D.K., Mafficini, A., et al., Australian Pancreatic Cancer Genome Initiative. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543 (2017), 65–71.
36. Shinbrot, E., Henninger, E.E., Weinhold, N., Covington, K.R., Göksenin, A.Y., Schultz, N., Chao, H., Doddapaneni, H., Muzny, D.M., Gibbs, R.A., et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 24 (2014), 1740–1750.
37. Shlien, A., Campbell, B.B., de Borja, R., Alexandrov, L.B., Merico, D., Wedge, D., Van Loo, P., Tarpey, P.S., Coupland, P., Behjati, S., et al., Biallelic Mismatch Repair Deficiency Consortium. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47 (2015), 257–262.
38. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
39. Stratton, M.R., Campbell, P.J., Futreal, P.A., The cancer genome. Nature 458 (2009), 719–724.
40. Swann, P.F., Waters, T.R., Moulton, D.C., Xu, Y.Z., Zheng, Q., Edwards, M., Mace, R., Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273 (1996), 1109–1111.
41. Tabori, U., Hansford, J.R., Achatz, M.I., Kratz, C.P., Plon, S.E., Frebourg, T., Brugières, L., Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin. Cancer Res. 23 (2017), e32–e37.
42. Tomasetti, C., Li, L., Vogelstein, B., Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 355 (2017), 1330–1334.
43. Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16 (2016), 275–287.
44. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Foppen, M.H.G., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
45. van Thuijl, H.F., Mazor, T., Johnson, B.E., Fouse, S.D., Aihara, K., Hong, C., Malmström, A., Hallbeck, M., Heimans, J.J., Kloezeman, J.J., et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 129 (2015), 597–607.
46. Weinstein, J.N., Akbani, R., Broom, B.M., Wang, W., Verhaak, R.G., McConkey, D., Lerner, S., Morgan, M., Creighton, C.J., Smith, C., et al., Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
47. Zahurancik, W.J., Klein, S.J., Suo, Z., Significant contribution of the 3′→5′ exonuclease activity to the high fidelity of nucleotide incorporation catalyzed by human DNA polymerase E. Nucleic Acids Res. 42 (2014), 13853–13860.
48. Zhang, J., Nichols, K.E., Downing, J.R., Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med., 374, 2016, 1391.